Tavette Neskorik serves as the Vice President of Clinical Operations. Ms. Neskorik has over 25 years of experience in the pharmaceutical and biotechnology industry, leading large operational teams in the execution of clinical trials ranging from early stage to late-stage drug development. Prior to joining Viking, she was a Senior Director of Clinical Operations at Mirati Therapeutics, a biotechnology company focused on the development of oncology therapies for the treatment of solid tumors. At Mirati she oversaw the clinical conduct of several global pivotal trials from initiation through NDA submission and approval. Previously, she served as Director of Clinical Operations for Optimer Pharmaceuticals, a biotechnology company which was acquired by Merck. During her tenure she oversaw the conduct of two large global pivotal trials from initiation through NDA submission and approval. She has also held positions or increasing responsibility at Synteract Inc. and PPD Development. Ms. Neskorik holds a BS in Psychology from Augusta State University.